Andreas Kapatais
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andreas Kapatais has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Christelos Kapatais
11st Department of Respiratory Medicine, Sotiria Hospital, Medical School, National and Kapodistrian University of Athens, GR-11527 Athens, Greece, Athens, Greece
2 shared publications - Nikolaos Martsoukos
Laboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, School of Health & Caring Sciences, University of West Attica (UniWA), Ag. Spyridonos Street, 12243 Athens, Greece
2 shared publications - Sotirios P. Fortis
Laboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, School of Health & Caring Sciences, University of West Attica (UniWA), 12243 Egaleo, Greece
2 shared publications - Anastasios G. Kriebardis
Laboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, School of Health & Caring Sciences, University of West Attica (UniWA), 12243 Egaleo, Greece
1 shared publication - Andreas Georgios Tsantes
Laboratory of Haematology and Blood Bank Unit, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece
1 shared publication - Andrianna Konstantelou
1st Department of Internal Medicine, General Hospital of Nikea “Agios Panteleimon”, 18454 Piraeus, Greece
1 shared publication
Latest Publications
- Open Access
Externally Validated Probabilistic Modeling of a Predefined Entecavir Resistance Pathway in HBV Using Independent Public Repositories
Background: Accurate interpretation of hepatitis B virus (HBV) polymerase sequences is essential for identifying antiviral resistance, particularly for high-genetic-barrier agents such as entecavir. Current resistance interpretation relies largely on deterministic rule-based systems that do not quantify uncertainty and are difficult to evaluate across independent datasets. We aimed to develop and externally validate a transparent probabilistic framework for reconstructing a predefined entecavir resistance pathway from HBV polymerase sequences. Methods: HBV polymerase sequences were retrieved from the NCBI GenBank database and curated through translation, quality control, and deduplication to create the development dataset. Reverse transcriptase (RT) positions were indexed using motif-anchored numbering based on the YMDD-family motif. A genotypic proxy for the entecavir resistance pathway was defined by lamivudine-associated background substitutions combined with entecavir-associated RT substitutions. A logistic regression model with probability calibration was trained and internally validated using prespecified performance metrics and thresholds. External validation was performed on an independent HBVdb dataset with preprocessing, model parameters, and thresholds frozen prior to evaluation. Results: The development dataset comprised 1174 unique polymerase sequences, of which 268 met the resistance pathway definition. Internal validation demonstrated perfect discrimination, consistent with the deterministic genotypic definition of the outcome. External validation on 11,513 independent HBVdb sequences demonstrated reproducible performance across repositories despite a markedly lower prevalence of the resistance pathway (2.2%), with preserved discrimination and stable threshold-based performance. Conclusions: This study presents a transparent and externally validated machine learning framework for probabilistic identification of the entecavir resistance pathway in HBV. The approach provides a transparent and reproducible probabilistic formalization of an established genotypic resistance definition and may serve as a methodological framework for standardized sequence-based resistance interpretation.
Open AccessExternally Validated Probabilistic Modeling of a Predefined Entecavir Resistance Pathway in HBV Using Independent Public Repositories
Background: Accurate interpretation of hepatitis B virus (HBV) polymerase sequences is essential for identifying antiviral resistance, particularly for high-genetic-barrier agents such as entecavir. Current resistance interpretation relies largely on deterministic rule-based systems that do not quantify uncertainty and are difficult to evaluate across independent datasets. We aimed to develop and externally validate a transparent probabilistic framework for reconstructing a predefined entecavir resistance pathway from HBV polymerase sequences. Methods: HBV polymerase sequences were retrieved from the NCBI GenBank database and curated through translation, quality control, and deduplication to create the development dataset. Reverse transcriptase (RT) positions were indexed using motif-anchored numbering based on the YMDD-family motif. A genotypic proxy for the entecavir resistance pathway was defined by lamivudine-associated background substitutions combined with entecavir-associated RT substitutions. A logistic regression model with probability calibration was trained and internally validated using prespecified performance metrics and thresholds. External validation was performed on an independent HBVdb dataset with preprocessing, model parameters, and thresholds frozen prior to evaluation. Results: The development dataset comprised 1174 unique polymerase sequences, of which 268 met the resistance pathway definition. Internal validation demonstrated perfect discrimination, consistent with the deterministic genotypic definition of the outcome. External validation on 11,513 independent HBVdb sequences demonstrated reproducible performance across repositories despite a markedly lower prevalence of the resistance pathway (2.2%), with preserved discrimination and stable threshold-based performance. Conclusions: This study presents a transparent and externally validated machine learning framework for probabilistic identification of the entecavir resistance pathway in HBV. The approach provides a transparent and reproducible probabilistic formalization of an established genotypic resistance definition and may serve as a methodological framework for standardized sequence-based resistance interpretation.
- Open Access
- 7 January 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (1) , 124
Microvesicle Profiles in Patients with HIV, HBV, and HCV Infections: An Exploratory Pilot Study
Microvesicles (MVs) are extracellular vesicles released from many cell types under physiological and pathological conditions, influencing viral transmission, immune regulation, and inflammation. This exploratory pilot study characterized and compared plasma MV profiles in patients infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Plasma samples (n = 125; HIV: 25, HBV: 50, HCV: 50) were analyzed using nanoparticle tracking analysis (NanoSight NS300) to assess MV size and concentration, classifying them as small (300 nm). Patients with HBV exhibited significantly larger mean MV size compared with both patients with HIV (131.5 ± 14.6 nm vs. 113.1 ± 14.0 nm, p < 0.0001) and HCV (131.5 ± 14.6 nm vs. 118.0 ± 18.5 nm, p = 0.0002). HCV infection showed higher concentrations of large MVs than HIV (p = 0.0022), while total and small MV levels did not differ. No sex-related differences were detected. Distinct MV size distributions appear linked to chronic viral infections, with HBV and HCV showing greater alterations than HIV. MVs may serve as potential biomarkers reflecting infection-associated biological processes; however, mechanistic, or functional roles were not assessed in this study and will require dedicated future investigations in larger controlled studies.
- 7 January 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (1) , 124
Open AccessMicrovesicle Profiles in Patients with HIV, HBV, and HCV Infections: An Exploratory Pilot Study
Microvesicles (MVs) are extracellular vesicles released from many cell types under physiological and pathological conditions, influencing viral transmission, immune regulation, and inflammation. This exploratory pilot study characterized and compared plasma MV profiles in patients infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Plasma samples (n = 125; HIV: 25, HBV: 50, HCV: 50) were analyzed using nanoparticle tracking analysis (NanoSight NS300) to assess MV size and concentration, classifying them as small (300 nm). Patients with HBV exhibited significantly larger mean MV size compared with both patients with HIV (131.5 ± 14.6 nm vs. 113.1 ± 14.0 nm, p < 0.0001) and HCV (131.5 ± 14.6 nm vs. 118.0 ± 18.5 nm, p = 0.0002). HCV infection showed higher concentrations of large MVs than HIV (p = 0.0022), while total and small MV levels did not differ. No sex-related differences were detected. Distinct MV size distributions appear linked to chronic viral infections, with HBV and HCV showing greater alterations than HIV. MVs may serve as potential biomarkers reflecting infection-associated biological processes; however, mechanistic, or functional roles were not assessed in this study and will require dedicated future investigations in larger controlled studies.